Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Futu Holdings Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.42 (market cap $9.43B), while Futu Holdings Ltd trades at $105.31 (market cap $14.74B). The key difference: Futu Holdings Ltd is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.47% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | FUTU | |
|---|---|---|
Market Cap | $9.43B | $14.74B |
Sector | Health | Financials |
52-Week High | $356.25 | $199.04 |
52-Week Low | $241.71 | $89.76 |
Enterprise Value | $9.18B | $14.59B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Futu Holdings Limited (FUTU) trades at $108.70, showing modest daily movement with a slight decline of 0.29%. The stock exhibits a bullish technical trend, supported by moving averages, while recent earnings have been mixed with two misses and one beat against expectations. Strong revenue growth and profitability margins highlight solid fundamental performance, though the company faces significant legal and regulatory scrutiny.
The outlook for FUTU is cautiously optimistic, driven by robust financial health and analyst support, but overshadowed by ongoing securities class action lawsuits alleging regulatory compliance failures. Key risks include legal liabilities and market sentiment pressure, while opportunities lie in sustained earnings growth and favorable valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
